REG - IP Group PLC - Directorate Change

IPAnnouncement

18/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230118:nRSR0431Na&default-theme=true

RNS Number : 0431N  IP Group PLC  18 January 2023

 FOR RELEASE ON  18 January 2023

 

IP Group plc - Appointment of Anita Kidgell as Non-executive Director

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), which develops
world-changing science and technology businesses, is delighted to announce the
appointment of Anita Kidgell as an independent Non-executive Director with
effect from 18 January 2023.

 

Ms Kidgell is currently Head of Corporate Strategy at GSK plc, one of the
world's leading healthcare companies and brings to the Board a rare
combination of a scientific background together with strategic and
communication experience in a leading listed company. Ms Kidgell has spent the
bulk of her career at GSK in a number of roles including clinical research,
science and product communications, strategy and investor relations.

 

Sir Douglas Flint, Chairman of IP Group, said: "We are delighted to welcome
Anita to the Board, where her experience in strategic development within the
life sciences sector and in investor communication will add a fresh dimension
to existing strengths on the Board. Her involvement in working at the heart of
one of life science's leading listed companies will be invaluable to IP Group
as we develop."

This announcement is made pursuant to Listing Rule 9.6.11R. There are no other
details required to be disclosed under Listing Rule 9.6.13R. There are no
further disclosures required under the Disclosure and Transparency Rules.

 

For more information, please contact:

 

 IP Group plc                                             www.ipgroupplc.com (http://www.ipgroupplc.com)
 Liz Vaughan-Adams, Communications                        +44 (0) 20 7444 0062/+44 (0) 7967 312125
 Portland
 Vic Wallin                                               +44 (0) 7973 823 119
 Alex Donaldson                                           +44 (0) 7516 729 702

 

Notes for editors

 

About IP Group

 

IP Group develops world-changing science and technology businesses across
life sciences, technology and cleantech (through Kiko Ventures). The Group has
a strong track record of success, having been the founder investor in a number
of high-profile companies including Oxford Nanopore Technologies plc, and has
one of the most exciting portfolios of high-growth businesses in Europe. The
Group also owns Parkwalk, the UK's largest growth EIS fund manager which backs
world-changing technologies emerging from the UK's leading universities and
research institutions. IP Group is listed on the Main Market of the London
Stock Exchange under the code IPO.

 

For more information, please visit our website at www.ipgroupplc.com
(http://www.ipgroupplc.com/) .

 

ENDS

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABRMPTMTJBBMJ